Chronic limb-threatening ischemia could benefit from growth hormone therapy for wound healing and limb salvage

Area of Science:

• Vascular Biology
• Endocrinology
• Regenerative Medicine

Background:

• Chronic limb-threatening ischemia (CLTI) often leads to amputation when revascularization is not possible.
• Current treatments, including stem cells and growth factors, show inconsistent results due to the need for arteriogenesis over angiogenesis.
• Diabetic patients with CLTI require improved limb perfusion and neuropathic response for wound healing.

Purpose of the Study:

• To evaluate the potential benefits and drawbacks of using Growth Hormone (GH) for treating CLTI.
• To analyze GH's effects on peripheral arteries and its role in improving cardiovascular complications.
• To explore GH as a therapeutic option for patients with limited alternatives.

Main Methods:

• Review of experimental and clinical studies on GH in the context of CLTI.
• Analysis of GH's pleiotropic effects, including arteriogenesis, angiogenesis, and redox balance.
• Focus on GH's impact on peripheral circulation and neuropathic responses.

Main Results:

• GH is a pleiotropic hormone with potential to improve perfusion and neuropathic response in ischemic limbs.
• GH may mitigate symptoms and cardiovascular complications associated with CLTI.
• GH's benefits for redox balance could aid wound healing in diabetic CLTI patients.

Conclusions:

• Growth hormone presents a promising therapeutic avenue for CLTI patients unresponsive to conventional treatments.
• Further investigation into GH's efficacy and safety is warranted for limb salvage and improved patient outcomes.
• GH could address the complex needs of CLTI, including vascular repair and nerve function.